Thermo Fisher Raises Full-Year Guidance as Pharma and Biotech Spending Snaps Back Faster Than Expected
Q2 2026 earnings call, July 23, 2026
Thermo Fisher Scientific delivered a quarter that surprised even its own management team, with organic revenue growth of 5% and adjusted EPS growth of 13% coming in well ahead of the guidance set just three months earlier. CEO Marc Casper called it "an outstanding quarter," and the numbers back him up: revenue grew 10% to $11.99 billion, adjusted operating margin expanded 90 basis points to 22.8%, and adjusted EPS reached $6.03. CFO Jim Meyer noted that Q2 revenue landed roughly $300 million ahead of prior guidance, with 2 percentage points of that coming from stronger organic growth alone, while adjusted EPS beat by $0.30. The company raised full-year revenue guidance to $47.4 billion to $48.1 billion and adjusted EPS guidance to $24.93 to $25.33, now implying 9% to 11% growth for the year.
The Real Story: Biotech Funding Is Finally Converting Into Revenue
The most important signal from the quarter is not the beat itself but what's driving it. Casper was direct about the source of the acceleration: "Definitely good momentum continues in pharma, but also biotech, clearly, we saw spending pick up. We've talked a lot about how activity had been picking up. But now it's good to see that's translating into the revenue as well." This matters because investors have spent the better part of two years waiting for biotech funding recoveries to show up in life sciences tools spending, and Thermo Fisher is now providing concrete evidence that the lag is closing. Management specifically pointed to bioproduction, clinical research, and the research and safety channel as the businesses capturing this reacceleration, with pharma and biotech, roughly 60% of total revenue, described by Casper as "progressing in a nice direction."
Notably, the company is not extending this optimism uniformly across end markets. Casper was careful to distinguish pharma and biotech, where the guidance raise is concentrated, from academic and government, which returned to low-single-digit growth in the quarter but where management is withholding a formal outlook upgrade. "We still think the market is going through a stabilization period," Casper said, adding that a second consecutive strong quarter would be needed before the company calls an inflection. That caution is a useful data point for investors trying to handicap the shape of the government-funded research recovery, which remains choppier than the corporate pharma recovery.
Analytical Instruments Segment Posts a Standout Beat
The Analytical Instruments segment was the single biggest surprise versus estimates, with both reported and organic revenue up 7% and adjusted operating margin expanding 420 basis points to 23.0%. Casper attributed this primarily to product cycle strength rather than simply a favorable comparison, pointing to new mass spectrometer launches unveiled at the American Society of Mass Spectrometry Conference in June, including the Orbitrap Tribrid Apex and Orbitrap Excedion systems, along with a new UHPLC platform. His framing of the underlying demand dynamic is worth noting for investors modeling the segment: "If you have really relevant innovation, customers get money." Electron microscopy also had a strong quarter, benefiting from continued semiconductor and advanced materials demand, with management citing strong bookings growth in addition to revenue.
Bioproduction Momentum Contrasts With Peer Weakness
Given recent commentary from competitors about softness and order pushouts in downstream bioprocessing, particularly resins, analysts pressed management on whether Thermo Fisher was seeing similar disruption. Casper's answer was unambiguous: the bioproduction business had "a really strong quarter" with no signs of the delays flagged elsewhere in the industry. He credited the company's single-use bioreactor platform, DynaDrive, for gaining share as it becomes standardized across the CDMO landscape, calling it "quickly becoming the favorite technology" among both contract manufacturers and innovator pharma companies. The recently acquired Solventum filtration and separation business is also running ahead of plan, with demand strong enough that Thermo Fisher is adding capacity, a detail that suggests the M&A integration is tracking better than the deal model likely assumed.
Capital Deployment: Microbiology Divestiture Funds Buybacks
Thermo Fisher's decision to use anticipated proceeds from the pending divestiture of its microbiology business to repurchase $1 billion of stock in the second quarter, ahead of the deal's actual close, is a notable capital allocation signal. Management explicitly framed this as a valuation call: the buyback was executed "based on an assessment of our valuation at that time." The microbiology unit, which generated $645 million of revenue in 2025, is expected to close in the third quarter, reducing 2026 revenue by about $200 million net of retained channel sales and cutting adjusted EPS by $0.05 this year, with a larger $0.15 dilutive impact expected in the first full year post-close. The company also continues to describe an active M&A pipeline in what Casper called a "highly fragmented industry," suggesting further bolt-on deals are likely rather than a one-off pause following Clario and the Solventum filtration business.
China Stabilizes, But Not Yet a Growth Contributor
China, approximately 7.5% of total revenue, returned to low-single-digit growth after a prolonged period of declines, with strength concentrated in pharma, biotech, and industrial and applied markets. Academic and government spending in China remains muted with no signs of improvement. Casper was measured about the significance of the return to growth, noting the region "is not accretive to our organic growth as a company yet, but we're taking the steps to put ourselves in a good position." He plans to spend additional time in China in the second half, including government relations engagement, indicating the company still views policy risk in the region as an active variable rather than a resolved one.
Guidance Mechanics and Second-Half Phasing
The $0.25 increase to the midpoint of full-year adjusted EPS guidance breaks down cleanly: $0.30 from the Q2 beat, $0.05 from a modestly better second-half revenue outlook, offset by a $0.05 drag from the microbiology divestiture and a $0.05 foreign exchange headwind tied to recent currency moves. Acquisitions are now expected to contribute $1.6 billion of revenue and $0.32 of adjusted EPS for the year, both raised from prior guidance. Full-year organic growth is now expected to land at the upper end of the 3% to 4% range, stepping up from 3% in the first half to 4% in the second half. Meyer pushed back on the idea that fourth-quarter growth would necessarily exceed the third quarter, telling analysts the two quarters should look "similar" despite an easier prior-year comparison in Q4, a clarification aimed at tempering expectations for a sharper back-half ramp.